Mumbai | April 18, 2014 12:33 (IST)
In the last six months alone, products made by some of India's largest drugmakers, including Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd and Dr. Reddy's Laboratories Ltd have been recalled from the United States.
April 15, 2014 23:40 (IST)
Cadila Healthcare and Zydus Pharmaceuticals on Tuesday said they have entered into a settlement agreement with Depomed Inc pertaining to patent infringement.
April 15, 2014 19:47 (IST)
Glenmark Pharmaceuticals has received $5 million as a milestone payment from Sanofi for a new drug to treat chronic auto-immune disorders, taking total payments received till date to $55 million.
April 15, 2014 14:06 (IST)
The Suprax recall is the second for India's fourth-largest drugmaker by sales, after pulling nearly 65,000 bottles from the U.S. in January last year because of discoloration.
April 14, 2014 08:16 (IST)
The BBC reported that 11 doctors and a GSK regional manager have been charged over alleged corruption between 2010 and 2012.
April 11, 2014 22:37 (IST)
The proposal comes in the wake of Sun Pharma's proposed $4-billion deal to merge Ranbaxy Laboratories with itself as the latter holds significant stake in Zenotech.
Hyderabad | April 09, 2014 18:43 (IST)
Rating agency Crisil has reaffirmed its 'A1+' rating on bank facilities of Ranbaxy Laboratories after Sun Pharmaceutical Industries' announcement to acquire a 100 per cent stake in it.
April 09, 2014 16:51 (IST)
Ranbaxy shares had surged 24 percent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy it for $3.2 billion.
New Delhi | April 09, 2014 15:32 (IST)
Lupin said its US subsidiary, Lupin Pharmaceuticals Inc has received final approval for its Pioglitazone tablets from the US Food and Drugs Administration to market generic version of Takeda Pharmaceuticals USA Inc's Actos tablets.
April 09, 2014 12:42 (IST)
We are confident that we will be able to get over the problems of Ranbaxy. These problems are temporary and none of the problems are going to stay forever. I think we have done it in the past, and I believe we know how to do it, this is how we feel. Otherwise we would not have taken this chance.
April 08, 2014 11:04 (IST)
In a big ticket acquisition, Sun Pharma yesterday announced that it will acquire Ranbaxy in a $4 billion all-stock deal. The combined entity of Sun-Pharma and Ranbaxy will become the largest drug company in India and one of the largest speciality generics company in the world.
April 07, 2014 15:16 (IST)
Mumbai-based Sun Pharma has said it will acquire troubled Indian drug maker Ranbaxy in a $4-billion (Rs. 24,000 crore at 60 rupees to the US dollar) deal.
Tokyo/Mumbai | April 07, 2014 14:17 (IST)
Sun Pharmaceutical Industries Ltd has agreed to buy generic drugmaker Ranbaxy Laboratories Ltd for $3.2 billion, betting it can fix factory quality glitches that plagued the current owner, Japan's Daiichi Sankyo Co, and got Ranbaxy India-made drugs barred from the United States.
Mumbai | April 07, 2014 08:53 (IST)
There are just 1,500 drug inspectors responsible for more than 10,000 factories in India, where one in every 22 locally made samples was of sub-standard quality according to a study carried out two years ago.
April 07, 2014 07:21 (IST)
Ranbaxy, India's biggest company by sales, is controlled by Japan's Daiichi Sankyo. All of its local units have been under the scanner of the US Food and Drug Administration for manufacturing violations. Currently, Ranbaxy cannot export generic drugs to the US, which is its most important market.
Hyderabad | April 06, 2014 18:50 (IST)
DRL had 21 active products in the proprietary products pipeline, of which six were in clinical development stage as on March 31, 2013, as per a filing with the US Food and Drug Administration last year.
London | April 04, 2014 18:14 (IST)
GlaxoSmithKline, facing allegations of bribery in China, has dismissed some employees in the country over failure to comply with expenses rules, a person familiar with the situation said on Friday.
Hyderabad | April 04, 2014 15:41 (IST)
The United States Patent and Trademark Office (the "PTO") issued a final office action rejecting Teva's application seeking a reissue of US Patent No. 5,800,808 (the "'808 Patent"), which was found to be invalid by the Court of Appeals for the Federal Circuit in July 2013
April 03, 2014 17:02 (IST)
Glenmark has completed preclinical studies and Phase 1 enabling good laboratory practise for the molecule, GRC 27864, and has filed a Phase 1 application for first-in-human trial with the MHRA, UK, Glenmark Pharma said in a BSE filing.
Zurich | April 03, 2014 15:49 (IST)
Novartis has taken Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday.